Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Cancer Res. 2019 Jan 1;79(1):133-145. doi: 10.1158/0008-5472.CAN-18-1968. Epub 2018 Oct 24.
Kras is a decisive oncogene in pancreatic ductal adenocarcinoma (PDAC). PIN1 is a key effector involved in the Kras/ERK axis, synergistically mediating various cellular events. However, the underlying mechanism by which PIN1 promotes the development of PDAC remains unclear. Here we sought to elucidate the effect of PIN1 on redox homeostasis in Kras-driven PDAC. PIN1 was prevalently upregulated in PDAC and predicted the prognosis of the disease, especially Kras-mutant PDAC. Downregulation of PIN1 inhibited PDAC cell growth and promoted apoptosis, partially due to mitochondrial dysfunction. Silencing of PIN1 damaged basal mitochondrial function by significantly increasing intracellular ROS. Furthermore, PIN1 maintained redox balance via synergistic activation of c-Myc and NRF2 to upregulate expression of antioxidant response element driven genes in PDAC cells. This study elucidates a new mechanism by which Kras/ERK/NRF2 promotes tumor growth and identifies PIN1 as a decisive target in therapeutic strategies aimed at disturbing the redox balance in pancreatic cancer. SIGNIFICANCE: This study suggests that antioxidation protects Kras-mutant pancreatic cancer cells from oxidative injury, which may contribute to development of a targeted therapeutic strategy for Kras-driven PDAC by impairing redox homeostasis.
Kras 是胰腺导管腺癌(PDAC)中的决定性致癌基因。PIN1 是参与 Kras/ERK 轴的关键效应因子,协同调节各种细胞事件。然而,PIN1 促进 PDAC 发展的潜在机制尚不清楚。在这里,我们试图阐明 PIN1 对 Kras 驱动的 PDAC 中氧化还原平衡的影响。PIN1 在 PDAC 中普遍上调,并预测了该疾病的预后,尤其是 Kras 突变型 PDAC。PIN1 的下调抑制了 PDAC 细胞的生长并促进了细胞凋亡,部分原因是线粒体功能障碍。沉默 PIN1 通过显著增加细胞内 ROS 显著损害了基础线粒体功能。此外,PIN1 通过协同激活 c-Myc 和 NRF2 来维持氧化还原平衡,以上调 PDAC 细胞中抗氧化反应元件驱动基因的表达。这项研究阐明了 Kras/ERK/NRF2 促进肿瘤生长的新机制,并将 PIN1 鉴定为扰乱胰腺癌氧化还原平衡的治疗策略中的决定性靶点。
这项研究表明,抗氧化作用可保护 Kras 突变型胰腺癌细胞免受氧化损伤,这可能有助于通过破坏氧化还原平衡来损害靶向治疗策略的发展,为 Kras 驱动的 PDAC 提供一种有针对性的治疗策略。